# Nasdaq

Type: Company (NDAQ)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/nasdaq
Canonical HTML page: https://gethealthbrief.com/entity/nasdaq

## Timeline

- **2026-03-18**: Financial Reporting — Lifeward scheduled to report Q4 and full-year 2025 financial results.
- **2026-03-13**: Shareholder Approval — Lifeward shareholders vote in favor of the strategic partnership with Oramed.
- **2026-03-11**: Nasdaq Compliance — Lifeward regains compliance with Nasdaq minimum bid price requirements.

## Recent coverage (3 stories)

### Heartflow Reports 40.5% Revenue Surge Despite Wider-Than-Expected Q4 Loss
2026-03-19 12:27:26 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Heartflow (NASDAQ: HTFL) reported a significant 40.5% year-over-year revenue increase in its latest quarterly results, though earnings per share fell short of analyst expectations. The company posted a loss of $0.29 per share, missing the consensus estimate of $0.16 as it continues to invest heavily in market expansion.
Full story: https://gethealthbrief.com/story/heartflow-q4-earnings-revenue-growth-eps-miss

### Hologic Short Interest Surges 71.7% as Market Sentiment Shifts Bearish
2026-03-15 10:07:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Hologic, Inc. (NASDAQ: HOLX) has experienced a dramatic 71.7% increase in short interest, signaling a significant shift in investor sentiment toward the medical technology leader. This surge suggests growing skepticism regarding the company's near-term growth prospects in its core women's health and diagnostics segments.
Full story: https://gethealthbrief.com/story/hologic-holx-short-interest-surge-analysis

### Lifeward and Oramed Secure Shareholder Approval for Strategic Biomedical Merger
2026-03-13 13:13:21 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.
Full story: https://gethealthbrief.com/story/lifeward-oramed-strategic-biomedical-partnership-approval

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.